Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Health
STAT+
Pharmalot
The Readout

Regeneron’s eczema problem & buybacks versus science

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan March 2, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for March 02, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

FDA oncology head wants advisory panels to keep voting…
FDA oncology head wants advisory panels to keep voting on new drugs
How Tennessee is creating new opportunities for doctors trained…
How Tennessee is creating new opportunities for doctors trained outside the U.S.
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories